Camurus AB's book value per share for the quarter that ended in Mar. 2026 was $7.98.
During the past 12 months, Camurus AB's average Book Value Per Share Growth Rate was 25.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 58.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 40.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 18.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Camurus AB was 152.00% per year. The lowest was -27.40% per year. And the median was 41.65% per year.
Camurus AB's current price is $61.01. Its book value per share for the quarter that ended in Mar. 2026 was $7.98. Hence, today's PB Ratio of Camurus AB is 7.65.
During the past 13 years, the highest P/B Ratio of Camurus AB was 21.89. The lowest was 4.80. And the median was 10.78.
Camurus AB (OTCPK:CAMRF) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Camurus AB Book Value per Share Related Terms
Camurus AB Book Value per Share Historical Data
* Premium members only.
The historical data trend for Camurus AB's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAMRF vs VRTX, REGN, ALNY: Book Value per Share Comparison
For the Biotechnology subindustry, Camurus AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Camurus AB's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB (CAMRF) has a Book Value per Share of $7.98 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Camurus AB and its competitors.
Is Camurus AB's Book Value per Share too high?
Camurus AB's current Book Value per Share is $7.98. Overall, Camurus AB has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Book Value per Share compare to VRTX and REGN?
Camurus AB's Book Value per Share of $7.98 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Camurus AB and its competitors. Camurus AB's current Book Value per Share is $7.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $74.85, compared to a current price of $61.01 — trading 18.5% below its estimated fair value. The current Book Value per Share is $7.98. Camurus AB's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Book Value per Share is $7.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $61.01 is trading 18.5% below its estimated GF Value™ of $74.85.
GuruFocus considers Camurus AB to be Modestly Undervalued.
Key valuation signals for CAMRF:
Book Value per Share: $7.98
GF Value™: $74.85 vs. price of $61.01 (18.5% below fair value)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
81GF Score
Get the complete analysis for CAMRF
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
